Inflexion is pleased to announce it has made a substantial investment into Upperton Pharma Solutions (“Upperton”), a UK-based specialist contract development and manufacturing organisation (“CDMO”) which has significant expertise in particle engineering for the pharmaceutical industry. Inflexion has invested alongside the founder and the management team who will continue to lead the business. The investment is being made from Inflexion Enterprise Fund V.
Click here to read the press release
Target – UPPERTON LIMITED (Upperton Pharma Solutions,Upperton Ltd,Upperton)
Buyer – Management Team
Buyer – Richard Johnson (Private Investor)
Seller – Shareholders
